Research programme: therapeutic agents - Astellas Pharma/MerLion PharmaceuticalsAlternative Names: Therapeutic agents research programme - Astellas Pharma/MerLion Pharmaceuticals
Latest Information Update: 19 Jan 2011
At a glance
- Originator Astellas Pharma; MerLion Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 11 Oct 2005 Early research in Undefined in Singapore (unspecified route)
- 11 Oct 2005 Early research in Undefined in Japan (unspecified route)